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ABSTRACT
TheNationalMarrowDonorProgram (NMDP)has facilitatedunrelateddonorhematopoietic cell transplants for
more than20years. In this timeperiod, therehavebeenmanychanges in clinical practice, including improvements
inHLA typing and supportive care, and changes in the source of stemcells. Availability of banked unrelated donor
cord blood (incorporated into the NMDP registry in 2000) as a source of stem cells has become an important
option for children with leukemia, offering the advantages of immediate availability for children with high-risk
disease, the need for a lesser degree of HLA match, and expanding access for those with infrequent HLA haplo-
types.Overall survival (OS) in childrenwith acute leukemia transplantedwithunrelateddonorbonemarrow (BM)
is markedly better in more recent years, largely attributable to less treatment-related mortality (TRM). Within
this cohort, 2-year survivalwasmarkedly better for patientswith acute lymphoblastic leukemia (ALL) infirst com-
plete response (CR1) (74%) versus second complete response (CR2) (62%)ormore advanced disease (33%). Sim-
ilar findings are observedwith patientswithAML, suggesting earlier referral to bonemarrow transplant (BMT) is
optimal for survival. Notably, this improvement over time was not observed in unmodified peripheral blood stem
cell (PBSC) recipients, suggesting unmodified PBSC may not be the optimal stem cell source for children.
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The National Marrow Donor Program (NMDP)
has facilitated unrelated donor hematopoietic cell
transplantation (HCT) in pediatric patients since
1987. With the NMDP celebrating its 20th anniver-
sary, it is an ideal time to reflect on the outcome of
HCT facilitated through this program in treating chil-
dren with acute leukemia, evaluate what has been
learned, and what we surmise the future holds.
Acute leukemia is the most prevalent type of cancer
in children, and the most frequent indication for unre-16lated donor HCT. Despite major advances in chemo-
therapy for acute leukemia, HCT remains the best
therapeutic option for a subset of patients with high-
risk disease at presentation, as well as for the majority
of patients who relapse. This review will focus on the
outcomes of HCT facilitated by the NMDP over the
past 20 years for pediatric patients with acute leukemia.
Data Collection
The study population included 1494 children\18
years of age who received an unrelated donor bone
NMDP Pediatric Acute Leukemia 17marrow transplant (BMT) following myeloablative
therapy for treatment of acute leukemia since the in-
ception of the NMDP in 1987 through March of
2006, at 1 of 102 transplant centers. Data from this co-
hort were collected on standard NMDP forms, and in-
cluded only patients for whom informed consent was
obtained. Four hundred one patients were omitted
from the study because of consent issues.
These data were grouped into 4 time periods (1987-
1995, 1996-1998, 1999-2002, and 2003-2006) chosen as
approximately equal in length (3-4 years) with similar
numbers of patients. A longer early period (1987-
1995) was chosen to have enough cases for analysis.
Statistical Analysis and Definitions
Probabilities of survival were calculated using the
Kaplan-Meier method. Probabilities of treatment-
related mortality (TRM) and relapse were calculated
using the cumulative incidence method. Chi-square
tests were used for pointwise rate comparisons. TRM
is defined as death without relapse. Relapse was treated
as a competing risk. Relapse and TRM were censored
at the occurrence of a second transplant.
Disease stage at conditioning was classified into 3
categories: first complete remission (CR1), second
complete remission (CR2), or advanced (relapse, pri-
mary induction failure, and third or greater complete
remission (CR3)). Myeloablative conditioning regi-
mens included 1 of the following: total body irradia-
tion (TBI) dose .500 cGy as a single fraction, TBI
dose .800 cGy regardless of the number of fractions,
melphalan (Mel) dose .150 mg/m2, busulfan dose
$9.5 mg/kg, any combination of Mel and Bu, or
any combination of cyclophosphamide (Cy), Etopo-
side (VP-16), and TBI. Based on the best available
typing data at the time of analysis, HLA matching
was classified into 3 categories (well-matched, par-
tially matched, and mismatched) according to a re-
cently developed algorithm that considers level of
HLA typing resolutions and matching at HLA-A,
-B, -C, and -DRB1 loci [1]. Well-matched cases
had either no identified HLA mismatches and
informative data at 4 loci or allele matching at
HLA-A, -B, and -DRB1. Partially matched pairs had
a defined, single locus mismatch and/or missing
HLA data. Mismatched cases had $2 allele or antigen
mismatches.
RESULTS
The annual number of pediatric transplants in all
diseases performed through the NMDP has steadily
increased over 20 years as shown in Figure 1. The
source of unrelated donor stem cells has changed
from solely bone marrow (BM), to include peripheral
blood stem cells (PBSC) in 1995, and umbilical cord
blood (UCB) in 2000 (Figure 1). The proportion oftransplants from UCB has increased briskly since
2000, when the NMDP first included cord blood units
(CBUs) in standard search algorithms, and UCB trans-
plants now represent 1/3 of all transplants for children
with acute leukemia. The use of PBSC has increased in
the last 8 years, but to a lesser extent than in adult prac-
tice, with a plateau in utilization in the last 4 years. The
lesser enthusiasm for PBSC in pediatric compared
with adult practice likely reflects published data indi-
cating higher rates of graft-versus-host disease
(GVHD) and lower survival in children receiving
unmodified PBSC from both related and unrelated
donors [2].
In our study population 1494 children with acute
leukemia have received unrelated donor BM trans-
plants facilitated through the NMDP. Patient and
transplant characteristics for these BM recipients are
shown in Table 1.
Survival
UCB and PBSC utilization has only been substan-
tial in the last 5 years. Therefore, in this report we fo-
cused on patients who received an unrelated donor BM
transplant. We selected to focus on patients with acute
leukemia, because our goal was to examine changes in
transplant outcomes over the 20 years that the NMDP
has facilitated unrelated donor transplantation, and the
analysis required a sufficient number of patients with
specific diagnoses to have been treated in each range
of years. Encouragingly, survival has improved over
time, with most of the improvement occurring since
2003 (Figure 2). Patients transplanted from 2003 to
2006 (n 5 308) had the best survival at 2 years at
58% (95% confidence interval [CI] 52%-64%). In
contrast, 2-year survival was 44% (95% CI 39%-
49%) for 404 patients transplanted in 1999 to 2002,
42% (95% CI 37%-47%) for 360 patients transplanted
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Figure 1.Number of pediatric transplants facilitated by the NMDP,
by year and stem cell source.
18 M. L. MacMillan et al.Table 1. Patient and Transplant Characteristics
1987-1995 1996-1998 1999-2002 2003-2006
Characteristic N % N % N % N %
Number of recipients 422 360 404 308
Follow-up time among survivors
Median months (range) 146.8 (42.5-216.7) 108.0 (10.5-135.4) 72.0 (3.4-100.9) 25.3 (3.1-51.4)
Recipient race
Caucasian 368 87 295 82 289 72 201 65
Other 54 13 65 18 115 28 104 34
Disease stage at conditioning
ALLTotal 317 75 218 61 245 61 195 63
ALL CR1 54 13 54 15 59 15 42 14
ALL CR2 143 34 103 29 116 29 107 35
ALL Advanced 120 28 61 17 70 17 46 15
AMLTotal 105 25 142 39 159 39 113 37
AML CR1 19 5 36 10 39 10 35 11
AML CR2 33 8 45 13 70 17 46 15
AML Advanced 53 13 61 17 50 12 32 10
Performance score at conditioning
90 to 100 331 78 275 76 320 79 236 77
10 to 80 91 22 84 23 59 15 22 7
Time from diagnosis to transplant
Median months (range) 21.9 (0-161) 15.7 (1-166) 17.7 (0-153) 16.8 (1-125)
\ 6 months 55 13 79 22 95 24 72 23
6 to 12 months 93 22 69 19 59 15 51 17
12 to 24 months 76 18 79 22 97 24 69 22
$ 24 months 198 47 133 37 151 38 116 38
HLA match CIBMTR definition
Well-matched 79 19 72 20 138 34 180 58
Partially matched 138 33 163 45 156 39 91 30
Mismatched 205 49 125 35 110 27 37 12
ALL indicates acute lymphoblastic leukemia, AML, acute myelogenous leukemia; CR1, CR2, first and second complete remission.in 1996 to 1998, and only 35% (95% CI 31%-40%) for
422 patients transplanted in 1987 to 1995 (P\ .001).
Similar improvements in survival in patients trans-
planted more recently are observed when examining
a subset of patients who underwent unrelated donor
BMT for acute leukemia in CR1 as shown in
Figure 3A, or CR2 as shown in Figure 3B.
The recent improvement in survival after unre-
lated donor BMT for patients with acute leukemia is
because of a decrease in treatment-related mortality
(TRM), which has dramatically declined over the last
20 years (Figure 4). The cumulative incidence of
TRM at 1 year after BMT for acute leukemia in CR1
and CR2 was 40% (95% CI 34%-46%) for patients
transplanted in 1987 to 1995, 28% (95% CI 23%-
34%) for the 1996 to 1998 cohort, 28% (95% CI
23%-33%) for the 1999 to 2002 cohort, and only
15% (95% CI 11%-20%) for the recent 2003 to
2006 cohort (P\ .001).
Methods for HLA testing have improved over the
last 20 years, with a higher proportion of more recent
transplant recipients having a known HLA well-
matched donor than in the past (Table 1). For recipi-
ents of well-matched donors, the probability of
2-year survival is better for more recently transplanted
patients (Figure 5A). Notably, the survival advantagein the 2003 to 2006 cohort is substantially greater
compared to earlier transplant recipients for those
who received recipients of the HLA mismatched do-
nor transplants (Figure 5B).
For patients with acute leukemia transplanted with
unrelated donor BMT in 2003 to 2006, survival is su-
perior for patients in CR1 than CR2, and significantly
worse for those in third or greater CR or relapse. As
shown in Figure 6 and Table 2, the probability of
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Figure 2. Probability of survival after unrelated donor for children
with acute leukemia, by transplant period. P-value at 2 years\.001.
NMDP Pediatric Acute Leukemia 19survival at 2 years after unrelated donor BMT for
patients with acute lymphoblastic leukemia (ALL)
was significantly better for children in CR1 (74%
[95% CI 60%-86%]), versus CR2 (62% [95% CI
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Figure 3. (A) Probability of survival after unrelated donor BMT for
children with acute leukemia in first complete remission (CR1) at
time of transplant, by transplant period. P-value at 2 years\.001.
(B) Probability of survival after unrelated donor BMT for children
with acute leukemia in second complete remission (CR2) at time
of transplant, by transplant period. P-value at 2 years 5 .001.
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Figure 4. Cumulative incidence of TRM in children with acute leu-
kemia in CR1 or CR2 at the time of BMT, by transplant period.
P-value\.001.52%-71%]) or in third or greater CR or relapse
at the time of BMT (33% [95% CI 20%-48%],
P\0.001). Similarly, the probability of 2-year survival
for patients with acute myelogenous leukemia (AML)
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Figure 5. (A) Probability of survival after HLA well-matched unre-
lated donor BMT for children with acute leukemia, by transplant
period. P-value at 2 years \.001. (B) Probability of survival after
HLA mismatched unrelated donor BMT for children with acute
leukemia, by transplant period. P-value at 2 years 5 .008.
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Figure 6. Probability of survival after unrelated donor BMT in 2003
to 2006 for children with acute leukemia, by disease state at time of
transplant. P-value at 2 years\.001 for ALL, 5.007 for AML.
20 M. L. MacMillan et al.Table 2. Survival by Disease
Year of HCT Number of Cases Survival at 1 year (95% CI) Survival at 2 years (95% CI)
ALL CR1 1987-1995 54 52% (39-65) 48% (35-61)
1996-1998 54 63% (50-75) 54% (40-67)
1999-2002 59 59% (47-71) 54% (42-67)
2003-2006 42 76% (62-88) 74% (60-86)
ALL CR2 1987-1995 143 48% (40-56) 43% (35-51)
1996-1998 103 51% (42-61) 44% (35-54)
1999-2002 116 57% (48-66) 50% (41-59)
2003-2006 107 71% (62-79) 62% (52-71)
ALL . CR2 or relapse 1987-1995 120 32% (24-40) 23% (16-31)
1996-1998 61 46% (34-58) 34% (22-46)
1999-2002 69 45% (33-57) 25% (15-35)
2003-2006 46 39% (26-53) 33% (20-48)
AML CR1 survival 1987-1995 19 68% (46-87) 42% (21-64)
1996-1998 36 39% (24-55) 31% (17-46)
1999-2002 39 56% (41-71) 36% (22-51)
2003-2006 35 80% (65-91) 69% (53-84)
AML CR2 survival 1987-1995 33 52% (35-68) 30% (16-47)
1996-1998 45 71% (57-83) 64% (50-78)
1999-2002 70 59% (47-70) 48% (37-60)
2003-2006 46 71% (58-84) 66% (52-79)
AML . CR2 or relapse 1987-1995 53 34% (22-47) 28% (17-41)
1996-1998 61 31% (20-43) 25% (15-36)
1999-2002 49 44% (31-58) 40% (27-54)
2003-2006 32 42% (26-60) 36% (20-53)
ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous leukemia; CR1, CR2, first and second complete remission.was significantly better for those patients in CR1 at the
time of BMT (69% [95% CI 53%-84%]) or CR2 (66%
[95% CI 52%-79%]) compared to patients in third
or greater CR or relapse (36% [95% CI 20%-53%],
P 5 0.007).
In contrast to the improved survival observed in
unrelated donor BMT recipients over time, there has
been no improvement in survival after transplantation
with unrelated donor unmodified PBSC over time, al-
though the period of observation has been short. Prob-
ability of survival at 2 years after PBSC transplant was
40% (95% CI 26-54) for 43 patients who received
a PBSC transplant from 1999 to 2002 compared to
46% (95% CI 37%-54%) for the 141 patients who re-
ceived a PBSC transplant from 2003 to 2006 (P5 .48).
The NMDP has been facilitating transplants using
unrelated donor UCB for a short time period so it is
not possible to examine survival over time with this
stem cell source.
DISCUSSION
Unrelated donor HCT is well established as effec-
tive therapy for children with high-risk leukemia [3-8].
The NMDP has facilitated unrelated donor HCT for
pediatric patients with acute leukemia since 1986. This
report demonstrates significant improvements in sur-
vival over a 20-year period, particularly since 2003.
Changes in chemotherapy regimens that have
occurred in parallel with changes in transplantation
approaches impact which children are referred fortransplantation. Intensification of post-induction che-
motherapy and the use of risk-adapted chemotherapy
have improved outcomes for children with ALL con-
siderably. Similarly, intensified therapy and better sup-
portive care have improved outcomes for children with
AML. The advances in upfront chemotherapy likely
means that currently treated children who relapse
and are referred for transplantation in CR2 have
more aggressive leukemia than children referred 20
years ago.
Improved strategies to identify patients with very
high-risk disease, such as those with Philadelphia chro-
mosome-positive ALL, have led to early referral of
these children for transplantation in CR1. As patients
transplanted in CR1 fare particularly well following
an unrelated donor BMT, these children now have
the opportunity to survive long term, whereas in the
past they continued on chemotherapy, suffered early
relapse, and frequently died without achieving CR2
and potentially benefiting from transplantation. The
U.S. Children’s Oncology Group is investigating the
role of unrelated donor transplant for the highest risk
subsets of children with leukemia (monosomy 7, induc-
tion failure, early relapse) utilizing improved strategy
for donor selection (studies of KIR match and mis-
match): these strategies may further increase the num-
ber of children likely to benefit from transplantation.
Although we have focused on children with acute
leukemia in this report, it is important to note that
similar improvements in survival have been noted in
children with non-malignant disorders including
NMDP Pediatric Acute Leukemia 21severe aplastic anemia (SAA) (Figure 7) and congenital
disorders of immune deficiency and metabolic disor-
ders [9].
A series of enhancements to the NMDP search
algorithm, including addition of high-resolution
matching, enhanced graphical interfaces, and the in-
troduction of HapLogic, have improved the ability
to identify optimal unrelated volunteer donors and
CBUs. A significant number of children in whom
HLA mismatches, or mismatch at HLA-C, would
have been overlooked by serologic typing may have
had their match grade improved by these strategies,
contributing to the notable reduction in TRM [10-12].
The selection of donors for BM donation based on
more stringent HLA typing has not contributed to
a decrease in number of transplantation procedures
performed for pediatric patients with acute leukemia,
as results following HLA partially matched and mis-
matched transplants have also improved over time,
and the utilization of UCB with less stringent HLA
matching requirements has expanded the pool of avail-
able donors.
In well-established transplant centers, patients
who receive a well-matched unrelated donor HCT
have similar outcomes as HLA-identical sibling
HCT recipients [13-17]. Our data lends further sup-
port for referral of children with high-risk acute leuke-
mia in CR1, or any acute leukemia in CR2-3, for
unrelated donor HCT similar to that for HLA-identi-
cal sibling donor transplants. Delaying referral for an
unrelated donor transplant increases the risk for
TRM and relapse, resulting in poor survival.
We observed a change in the stem cell source over
time, particularly with the recent growth of the use of
UCB. In contrast, the use of PBSC has not increased
in recent years. This may be due in part to less expe-
rience in the HLA-matched sibling donor setting for
pediatric patients secondary to small donor size. More
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Figure 7. Probability of survival after unrelated donor BMT for chil-
dren with SAA by transplant period. Dataset includes additional re-
cipients with non-myeloablative conditioning regimens. Pointwise
P-value at 2 years\.001.importantly, the limited utilization of this stem cell
source may be because of recent reports suggesting
poorer outcomes after PBSC compared to BM trans-
plantation in children [18]. Our data suggest that in
contrast to BM recipients, no improvement in survival
after unmodified PBSC transplants has been observed
in children. Whether T cell-depleted (CD34 de-
pleted) PBSCs will improve outcomes for children
with leukemia remains to be explored. Reported
data has shown similar outcomes in unrelated donor
UCB and BM recipients [16,19,20]. An ongoing na-
tional randomized study comparing outcomes using
single or double cord blood grafts for transplantation
may importantly change clinical practice in this area
in the next 5 years.
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